Venaxis Inc news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

APPY 3.57 -0.10 (-2.72%)
price chart
Venaxis Reports Option Inducement Grants for New Employees Under NASDAQ ...
CASTLE ROCK, Colo., Sept. 23, 2016 /PRNewswire/ -- Venaxis�, Inc. (Nasdaq: APPY), announced that on September 21, 2016, the Company approved the grant of stock options to six new employees, hired in connection with the Company's acquisition of ...
Venaxis Issues Shareholder Update
20, 2016 /PRNewswire/ -- Venaxis�, Inc. (Nasdaq: APPY), announced today that following its acquisition of BiOptix Diagnostics, Inc., ("BiOptix") that was announced on September 13, 2016, Venaxis has issued the following letter to its shareholders. The ...
Big Venaxis shareholder, company CEO in mudslinging melee  9NEWS.com
Venaxis Announces Acquisition of BiOptix
13, 2016 /PRNewswire/ -- Venaxis�, Inc. (Nasdaq: APPY), announced today that it has acquired BiOptix Diagnostics, Inc., ("BiOptix") a Boulder, CO-based privately-held company. BiOptix has developed a proprietary Enhanced Surface Plasmon Resonance ...
Venaxis buys drug discovery technology firm BiOptix Diagnostics  Seeking Alpha
Venaxis Inc (NASDAQ:APPY) Is Finally Poised For Growth
Venaxis Inc (NASDAQ:APPY) just announced its acquisition of biomedical device company BiOptix, and it looks as though markets are uncertain as to what the transaction means for the company going forward.
Venaxis Inc. APPY (US: Nasdaq)
Venaxis Inc. APPY (U.S.: Nasdaq). search. View All companies. AT CLOSE 3:59 PM EDT 09/20/16. $3.70 USD; -0.84 -18.50%.
Venaxis, Inc. (NASDAQ:APPY) Reported Basic Consolidated EPS Of $-2.2607 For ...
Coming to basic EPS from continuing operations, Venaxis, Inc. (NASDAQ:APPY) reported $-2.2607 for the annual period ended 2015-12-31.
What Price Target Did Brokers Issue On Venaxis, Inc. (APPY) This Week?
02/10/2016 - Venaxis, Inc. had its “hold” rating reiterated by analysts at Canaccord Genuity. They now have a USD 0.5 price target on the stock.
INVESTOR ALERT: Class Action Lawsuit Against Venaxis, Inc. Announced By Glancy ...
LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Colorado on behalf of a class (the “Class”) comprising purchasers of the securities ...
Venaxis Receives FDA "Not Substantially Equivalent" Response on APPY1 510(k ...
29, 2015 /PRNewswire/ -- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on advancing commercialization of its CE Marked APPY1™ Test, a rapid blood test for aiding in identifying children, adolescent, and young adult patients in ...
Venaxis Inc (APPY) Stock Crashes On FDA's “Not Substantially Equivalent ...  Bidness ETC
Stocks to Keep Your Eyes on Neothetics Inc (NASDAQ:NEOT), Venaxis Inc (NASDAQ ...
Shares of Neothetics Inc (NASDAQ:NEOT) flew +14.58% to $1.20 at 2:06 PM EDT. The stock attained the volume of 2.06 Million shares recently versus average trading volume of 793,682.00 shares.